Allarity TherapeuticsALLR +2.34%24 PB Ratio is 3.00 as of Jun. 26, 2026, which is 27% above its 10-year median of 2.36. GuruFocus rates ALLR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Allarity Therapeutics ranks worse than 51.54% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allarity Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allarity Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Allarity Therapeutics (ALLR) has a PB Ratio of 3.00 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Allarity Therapeutics and its competitors. This is 27% above median its historical median of 2.36. Over the past decade, Allarity Therapeutics' PB Ratio has ranged from 1.36 to 4.05. According to the industry distribution chart, Allarity Therapeutics ranks #635 out of 1232 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Allarity Therapeutics' PB Ratio too high?
Allarity Therapeutics' current PB Ratio of 3.00 is 27% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 4.05. The Biotechnology industry median PB Ratio is 2.80. Allarity Therapeutics' value of 3.00 is 7.1% above this industry median. Based on the distribution chart, Allarity Therapeutics ranks #635 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Allarity Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' PB Ratio compare to OTLC and MRKR?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #635 out of 1232 companies for PB Ratio. This places Allarity Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Allarity Therapeutics' value of 3.00 is 7.1% above this benchmark. Historically, Allarity Therapeutics' own PB Ratio has ranged from 1.36 to 4.05 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 2.80, Allarity Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allarity Therapeutics's current PB Ratio of 3.00 is 7.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Allarity Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allarity Therapeutics's current PB Ratio is 3.00, which is 27% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current PB Ratio of 3.00. The current PB Ratio is 3.00, which is 27% above median its 10-year median of 2.36 and 7.1% above the Biotechnology industry median of 2.80. Allarity Therapeutics' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current PB Ratio is 3.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
24GF Score
Get the complete analysis for ALLR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALLR has been successfully added to your 
